AI for Early Identification of Breast Cancer – Efficient and Accurate Diagnosis

By Michael Awood

September 15, 2023

Breast cancer is the second leading cause of cancer death in women. Early identification can ease this to ensure early access to treatment. Developed nations have vast mammography screening programs, but interpreting the images is still hard. The accuracy of cancer detection varies widely among experts, and the potential for improvement is significant. False positives can lead to patient anxiety, unnecessary follow-up, and invasive diagnostic procedures. Sometimes screening cannot identify cancers until they are more advanced and less amenable to treatment.

Artificial Intelligence (AI) can overcome this challenge. Studies show it can outperform human experts in many medical image analysis tasks. This leads us to evaluate AI’s potential to augment the early identification process of breast cancer through high-quality images.

Researchers recently tested a new AI system that predicts breast cancer using large datasets from the UK and the USA. The system outperformed radiologists in daily predictions, according to the researchers. They confirmed these observations with an independently conducted reader study. The system could generalize across different screening populations and settings without additional training data.

The AI system might reduce the workload involved in the double-reading process used in the UK while preserving the standard of care. The system could also provide automated, immediate feedback in the screening setting. This technology can sort cases at the risk level, making it possible to screen efficiently even with a limited workforce.

Overall, the AI was better than radiologists at identifying breast cancer. These results held across two large datasets that represent different screening populations and practices. However, the optimal use of the AI system within clinical workflows remains to be determined.

Cover image taken from the journal article. 

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.